Abstract
Exostosin 1/Exostosin 2 (EXT1/EXT2) were recently described by Sethi et al.1 as 2 new proteins and putative antigens in secondary membranous nephropathy, which were frequently associated with autoimmune findings of an underlying autoimmune disease, such as systemic lupus erythematosus (SLE) or mixed connective tissue disease. To date, limited studies have been published to validate and explore their clinical and pathological significance. In this study we aimed to evaluate the expression of EXTs, their clinicopathologic features, and the prognosis for EXT1/2–positive membranous lupus nephritis (MLN).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
